The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease
- PMID: 34017059
- PMCID: PMC8178320
- DOI: 10.1038/s12276-021-00614-x
The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease
Abstract
Imbalance between fat production and consumption causes various metabolic disorders. Nonalcoholic fatty liver disease (NAFLD), one such pathology, is characterized by abnormally increased fat synthesis and subsequent fat accumulation in hepatocytes1,2. While often comorbid with obesity and insulin resistance, this disease can also be found in lean individuals, suggesting specific metabolic dysfunction2. NAFLD has become one of the most prevalent liver diseases in adults worldwide, but its incidence in both children and adolescents has also markedly increased in developed nations3,4. Progression of this disease into nonalcoholic steatohepatitis (NASH), cirrhosis, liver failure, and hepatocellular carcinoma in combination with its widespread incidence thus makes NAFLD and its related pathologies a significant public health concern. Here, we review our understanding of the roles of dietary carbohydrates (glucose, fructose, and fibers) and the gut microbiota, which provides essential carbon sources for hepatic fat synthesis during the development of NAFLD.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Fructose as a key player in the development of fatty liver disease.World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. World J Gastroenterol. 2013. PMID: 23482247 Free PMC article. Review.
-
The role of the microbiome in NAFLD and NASH.EMBO Mol Med. 2019 Feb;11(2):e9302. doi: 10.15252/emmm.201809302. EMBO Mol Med. 2019. PMID: 30591521 Free PMC article. Review.
-
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25. Free Radic Biol Med. 2017. PMID: 27890642
-
Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.Pharmacol Res. 2019 Mar;141:418-428. doi: 10.1016/j.phrs.2019.01.026. Epub 2019 Jan 15. Pharmacol Res. 2019. PMID: 30658094 Review.
-
Rodent Models of Nonalcoholic Fatty Liver Disease.Digestion. 2020;101(5):522-535. doi: 10.1159/000501851. Epub 2019 Oct 10. Digestion. 2020. PMID: 31600750 Review.
Cited by
-
The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review.Life (Basel). 2022 Jun 5;12(6):839. doi: 10.3390/life12060839. Life (Basel). 2022. PMID: 35743870 Free PMC article. Review.
-
Dietary sodium acetate and sodium butyrate improve high-carbohydrate diet utilization by regulating gut microbiota, liver lipid metabolism, oxidative stress, and inflammation in largemouth bass (Micropterus salmoides).J Anim Sci Biotechnol. 2024 Apr 3;15(1):50. doi: 10.1186/s40104-024-01009-4. J Anim Sci Biotechnol. 2024. PMID: 38566217 Free PMC article.
-
The Impact and Burden of Dietary Sugars on the Liver.Hepatol Commun. 2023 Nov 6;7(11):e0297. doi: 10.1097/HC9.0000000000000297. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37930128 Free PMC article. Review.
-
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.Nutrients. 2024 Jul 11;16(14):2220. doi: 10.3390/nu16142220. Nutrients. 2024. PMID: 39064665 Free PMC article. Review.
-
Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.Int J Mol Sci. 2022 Oct 3;23(19):11710. doi: 10.3390/ijms231911710. Int J Mol Sci. 2022. PMID: 36233011 Free PMC article. Review.
References
-
- Zhou J, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851–1864. - PubMed
-
- Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA. 2002;288:1728–1732. - PubMed
-
- Tso P, Pitts V, Granger DN. Role of lymph flow in intestinal chylomicron transport. Am. J. Physiol. 1985;249:G21–G28.. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical